Aerie Pharmaceuticals Inc (AERI)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Rajkumar Kannan
Employees:
380
7020 KIT CREEK ROAD, SUITE 270, RESEARCH TRIANGLE PARK, NC 27709
919-313-9650

Aerie Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) and Rocklatan. The company also develops AR-15512 to treat signs and symptoms of dry eye.

Data derived from most recent annual or quarterly report
Market Cap 737.948 Million Shares Outstanding48.39 Million Avg 30-day Volume 526.29 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.56
Price to Revenue3.3818 Debt to Equity-1.9062 EBITDA-15.066 Million
Price to Book Value0.0 Operating Margin-12.4857 Enterprise Value863.64 Million
Current Ratio2.271 EPS Growth0.798 Quick Ratio1.848
1 Yr BETA 0.9195 52-week High/Low 15.37 / 4.81 Profit Margin-17.0865
Operating Cash Flow Growth115.3528 Free Cash Flow to Firm (FCFF) TTM -7.134 Million Free Cash Flow to Equity (FCFE) TTM-23.228 Million
Altman Z-Score-2.8223
View SEC Filings from AERI instead.

View recent insider trading info

Aerie Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AERI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AERI

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-11-21 by MCHUGH JULIE
  • 4: filed on 2022-11-21 by MCGRAW BENJAMIN F III
  • 4: filed on 2022-11-21 by MCDONNELL PETER J
  • 4: filed on 2022-11-21 by KOPCZYNSKI CASEY C.
  • 4: filed on 2022-11-21 by LANG PETER FREDERICK
  • 4: filed on 2022-11-21 by LAROCCA JOHN
  • 4: filed on 2022-11-21 by GRYSKA DAVID W
  • 4: filed on 2022-11-21 by DU TOIT MICHAEL
  • 4: filed on 2022-11-21 by CROARKIN RICHARD
  • 4: filed on 2022-11-21 by CALABRESE JEFFREY

    • Events (8k)

  • 8-K: filed on 2022-11-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-18:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-11-07:
    Item 8.01: Other Events
  • 8-K: filed on 2022-09-13:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-23:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-01:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GRYSKA DAVID W

    • Director
    		 0 2022-11-21 1

    MCGRAW BENJAMIN F III

    • Director
    		 0 2022-11-21 1

    MCHUGH JULIE

    • Director
    		 0 2022-11-21 1

    MCDONNELL PETER J

    • Director
    		 0 2022-11-21 1

    KOPCZYNSKI CASEY C. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2022-11-21 1

    DU TOIT MICHAEL

    • Director
    		 0 2022-11-21 1

    CROARKIN RICHARD

    • Director
    		 0 2022-11-21 1

    LAROCCA JOHN GENERAL COUNSEL

    • Officer
    		 0 2022-11-21 1

    KANNAN RAJ CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2022-11-21 1

    CALABRESE JEFFREY VICE PRESIDENT OF FINANCE

    • Officer
    		 0 2022-11-21 2

    LANG PETER FREDERICK CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2022-11-21 1

    MITRO THOMAS A PRESIDENT AND COO

    • Officer
    		 81,418 2022-02-07 0

    HOLLANDER DAVID CHIEF R&D OFFICER

    • Officer
    		 30,749 2022-02-04 0

    MCGINLEY KATHLEEN CHRO & VP, CORP SERVICES

    • Officer
    		 23,993 2022-01-30 0

    STATEN CHRISTOPHER INTERIM CFO

    • Officer
    		 21,710 2021-08-14 0

    CAGLE GERALD D.

    • Director
    		 27,850 2021-06-17 0

    ANIDO VICENTE JR CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 243,896 2021-02-23 0

    RUBINO RICHARD J CHIEF FINANCIAL OFFICER

    • Officer
    		 353,937 2021-02-23 0

    GOLDBERG MURRAY A

    • Director
    		 36,050 2020-05-18 0

    FORESITE CAPITAL MANAGEMENT II, LLC

    FORESITE CAPITAL FUND II, L.P.

    FORESITE CAPITAL FUND III, L.P.

    FORESITE CAPITAL FUND IV, L.P.

    FORESITE CAPITAL MANAGEMENT III, LLC

    FORESITE CAPITAL MANAGEMENT IV, LLC

    TANANBAUM JAMES B.

    • 10% Owner
    		 No longer subject to file 2020-02-27 0

    FORESITE CAPITAL MANAGEMENT IV, LLC

    FORESITE CAPITAL FUND IV, L.P.

    TANANBAUM JAMES B.

    • 10% Owner
    		 5,524,591 2019-12-20 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    DEERFIELD PARTNERS, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 5,853,502 2018-07-23 0

    FORESITE CAPITAL MANAGEMENT II, LLC

    FORESITE CAPITAL FUND II, L.P.

    FORESITE CAPITAL MANAGEMENT III, LLC

    FORESITE CAPITAL FUND III, L.P.

    TANANBAUM JAMES B.

    • 10% Owner
    		 3,643,191 2017-05-26 0

    DUYK GEOFFREY M

    • Director
    		 3,400 2017-02-14 0

    MEHRA ANAND

    • Director
    		 469,591 2015-04-14 0

    LEVY BRIAN CHIEF MEDICAL OFFICER

    • Officer
    		 16,313 2015-02-25 0

    CLARUS LIFESCIENCES II, L.P.

    CLARUS VENTURES II GP, L.P.

    CLARUS VENTURES II, LLC

    GALAKATOS NICHOLAS

    HENNER DENNIS

    LIPTAK ROBERT

    SIMON NICHOLAS

    STEINMETZ MICHAEL

    WHEELER KURT

    • Director
    • 10% Owner
    		 0 2015-01-28 0

    TPG GROUP HOLDINGS (SBS) ADVISORS, INC.

    BONDERMAN DAVID

    COULTER JAMES G

    • FORMER 10% OWNER (2)(3)(4)FORMER 10% OWNER (2)(3)(4)FORMER 10% OWNER (2)(3)(4)
    		 No longer subject to file 2014-11-25 0

    ACP IV, L.P.

    JANNEY DANIEL

    NOHRA GUY P

    ACMP IV LLC

    • 10% Owner
    		 No longer subject to file 2014-07-16 0

    SOFINNOVA VENTURE PARTNERS VII L P

    SOFINNOVA MANAGEMENT VII, L.L.C.

    HEALY JAMES

    BUATOIS ERIC

    POWELL MICHAEL

    • 10% Owner
    		 No longer subject to file 2014-07-09 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 22:15:04 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 21:45:04 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 21:15:04 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 20:45:03 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 20:15:04 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 19:45:03 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 19:15:03 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 18:45:04 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 18:15:03 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 17:45:03 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 17:15:03 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 16:45:03 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 16:15:04 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 15:45:03 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 15:15:03 UTC 2.9937 0.8263 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 14:45:03 UTC 3.2468 0.5732 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 14:15:03 UTC 3.2468 0.5732 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 13:45:04 UTC 3.2468 0.5732 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 13:15:03 UTC 3.2468 0.5732 1000000
    AERIE PHARMACEUTICALS INC AERI 2022-11-21 12:45:03 UTC 3.2468 0.5732 950000

    Current Active Short Positions

    Get more info on our International short position coverage here

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Defensive Long Fund AERI -40.0 shares, $-540.0 2020-03-31 N-PORT
    AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund AERI -112.0 shares, $-2152.64 2019-09-30 N-PORT

    Short Position History (International Only)

    Holder Net Short Position Position Date Origin
    HBK Investments L.P. Aerie Pharmaceuticals Inc. 0.51% 2015-10-16 GERMANY
    HBK Investments L.P. Aerie Pharmaceuticals Inc. 0.7% 2015-10-21 GERMANY
    HBK Investments L.P. Aerie Pharmaceuticals Inc 0.8% 2015-10-26 GERMANY
    HBK Investments L.P. Aerie Pharmaceuticals Inc 0.79% 2015-12-07 GERMANY
    HBK Investments L.P. Aerie Pharmaceuticals Inc 0.69% 2016-01-11 GERMANY
    HBK Investments L.P. Aerie Pharmaceuticals Inc 0.59% 2016-02-18 GERMANY

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments